Causes of death in men undergoing androgen suppression therapy for newly diagnosed localized or recurrent prostate cancer

Cancer

Volumn 113, Issue 12, 2008, Pages 3290-3297

  D'Amico, Anthony V ^a   Chen, Ming Hui ^b   Renshaw, Andrew A ^a   Loffredo, Marian ^a   Kantoff, Philip W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Androgen suppression therapy; Comorbidity; Prostate cancer; Survival

Indexed keywords

FLUTAMIDE; GONADORELIN AGONIST;

ADULT; AGED; ANDROGEN DEPRIVATION THERAPY; ANDROGEN SUPPRESSION THERAPY; ARTICLE; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RADIOTHERAPY; CAUSE OF DEATH; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HAZARD RATIO; HUMAN; MAJOR CLINICAL STUDY; MALE; ORCHIECTOMY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 57649114702     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23970     Document Type: Article

References (22)

1. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448-4456.
2. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen deprivation therapy. J Clin Oncol. 2006;24:3979-3983.
3. D'Amico AV, Denham JW, Crook J, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol. 2007;25:2420-2425.
4. Tsai H, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst. 2007;99:1516-1524.
5. D'Amico AV, Chen M, Renshaw AA, Loffredo M, Kantoff PW. Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA. 2008;299:289-295.
6. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA. 2004;291:2441-2447.
7. Roach M III, Bae K, Speight J, et al. Short-term neoadjuvant androgen deprivation therapy and external bean radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J Clin Oncol. 2008;26:585-591.
8. Pilepich MV, Winter K, Lawton CA, et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - long-term results of phase III RTOG 85-31. Int J Radiat Oncol Biol Phys. 2005;61:1285-1290.
9. Hanks GE, Pajak TF, Porter A, et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 9202. J Clin Oncol. 2003;21:3972-3978.
10. Beahrs OH, Henson DE, Hunter RVP. American Joint Committee on Cancer: Manual for Staging Cancer. 4th ed. Philadelphia, PA: JP Lippincott; 1992.
11. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-500.
12. Gaynor JJ, Feuer EJ, Tan CC, et al. On the use of cause-specific failure and conditional failure probabilities: examples from clinical oncology data. J Am Stat Assoc. 1993;88:400-409.
13. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988;16:1141-1154.
14. Klein JP, Moeschberger ML. Semiparametric proportional hazards regression with fixed covariates. In: Klein JP, Moeschberger ML, eds. Survival Analysis: Techniques for Censored and Truncated Data. 2nd ed. New York, NY: Springer; 2003:243-293.
15. Roach M III, Hanks G, Thames H Jr, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65:965-974.
16. D'Amico AV, Whittington R, Malkowicz SB, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280:969-974.
17. D'Amico AV, Moul J, Carroll P, Sun L, Lubeck D, Chen M. Surrogate marker for prostate cancer specific mortality following radical prostatectomy or radiation therapy. J Natl Cancer Inst. 2003;95:1376-1383.
18. Klein JP. Modeling competing risks in cancer studies. Stat Med. 2006;25:1015-1034.
19. Beyer DC, McKeough T, Thomas T. Impact of short course neoadjuvant hormonal therapy on overall and cancer-specific survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2005;61:1299-1305.
20. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E. Androgen-deprivation therapy does not impact cause-specific or overall survival after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2006;65:669-677.
21. Siagal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS;the Urologic Disease in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer. 2007;110:1493-1500.
22. Wirth MP, See WA, McLeod DG, Iversen P, Morris T, Carroll K;Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol. 2004;172:1865-1870.